<DOC>
	<DOCNO>NCT00875771</DOCNO>
	<brief_summary>The purpose study determine efficacy safety biweekly scheme Capecitabine Irinotecan , plus bevacizumab patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan , Capecitabine Bevacizumab Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description>The purpose study determine efficacy safety biweekly scheme Capecitabine Irinotecan , plus bevacizumab patient metastatic colorectal cancer . - Capecitabine : 1000 mg/m2 , bid , oral , day 2-8 . Every 2 week - Irinotecan : 175 mg/m2 , iv infusion 90 minute , day 1 , every 2 week - Bevacizumab : 5 mg/kg day 1 , every 2 Weeks</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Age &gt; 18 year old ( men woman ) 2 . ECOG Performance Status ≤ 2 . 3 . Histologically confirm colorectal adenocarcinoma , metastatic disease . 4 . No surgery option 5 . No previous chemotherapy , except adjuvant treatment finish least 6 month study inclusion 6 . Have least one measurable lesion accord RECIST criterion 7 . At least 3month life expectancy . 8 . Written informed consent give . 1 . Patients previously receive systemic treatment ( example , cytostatic chemotherapy active/passive immunotherapy ) advance metastatic disease . 2 . Patients previously treat bevacizumab 3 . Prior adjuvant neoadjuvant treatment nonmetastatic disease ( M0 ) allow , long conclude least 6 month begin treatment study . 4 . If adjuvant treatment previously administer , patient show progression disease treatment 6 month follow termination thereof . 5 . Prior radiotherapy allow administer target lesion select study , unless progression say lesion irradiated field document , long treatment conclude least 4 week begin study . 6 . Prior surgical treatment disease stage IV allow . 7 . Only non evaluable disease ( non measurable ) ascitis , pleural effusion , diffuse hepatic , osseous metastasis 8 . History another neoplastic disease last five year , exception cure basal cell carcinoma skin cervical carcinoma situ . 9 . History indication CNS disease ( example , primary brain tumor , uncontrolled convulsion standard medical treatment , cerebral metastasis type history ictus ) physical examination . 10 . Medication peripheral vascular disease , grade II high . Furthermore , patient myocardial infarction year prior begin treatment study exclude . 11 . History psychiatric disability investigator considers clinically significant , prevents patient grant informed consent interferes compliance take oral medication 12 . Clinically significant cardiovascular disease ( i.e. , active ) , example , uncontrolled hypertension , unstable angina , congestive heart failure , class II high New York Heart Association ( NYHA ) , severe cardiac arrhythmia 13 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability take oral medication . 14 . Patients subject organ allograft require immunosuppressive treatment . 15 . Severe , noncicatrized osseous fracture , wound ulcer . 16 . Indications hemorrhagic diathesis coagulopathy . 17 . Severe , uncontrolled intercurrent infection severe , uncontrolled concomitant disease . 18 . Moderate severe renal failure [ creatinine clearance low 30 ml/min ( calculate accord CockcroftGault Formula ) ] serum creatinine &gt; 1.5 x upper limit normal ( ULN ) . 19 . Any following laboratory value : Absolute neutrophils count ( ANC ) ≤ 1.5 x 109/l . Platelet count ≤ 100 x 109/l . Hemoglobin ≤ 9 g/dl . INR &gt; 1.5 . Total bilirubin &gt; 1.5 ULN . ALS and/or AST &gt; 2.5 x ULN &gt; 5 x ULN ( case hepatic metastasis ) . Alkaline phosphatase &gt; 2.5 x ULN 5 x ULN ( case hepatic metastasis ) , &gt; 10 x ULN ( case bone metastasis ) . 20 . History unexpected serious adverse event fluoropyrimidine treatment know dihidropyrimidine dehydrogenase ( DPD ) deficiency . 21 . Patients subject major surgical procedure , open biopsy patient significant traumatic injures 28 day time initial study treatment , patient major surgery procedure planning study period . Fine needle aspiration biopsy 7 day initial study . 22 . Use full dose oral parenteral anticoagulant ( least 10 day initial study treatment thrombolytic agent . Low dose warfarin allow , INR ≤ 1.5 23 . Subject require chronic use high dose aspirin ( &gt; 325 m/day ) nonsteroidal antiinflammatory treatment ( know inhibit platelet function dos use treat chronic inflammatory disease ) . 24 . Pregnant ( serum positive pregnancy test ) lactate woman . 25 . Received investigational drug agent/ procedure , i.e . participation another treatment trial within 30 day randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>BEVACIZUMAB</keyword>
	<keyword>CAPECITABINE</keyword>
	<keyword>IRINOTECAN</keyword>
</DOC>